Literature DB >> 8582469

Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity.

B Klemetsdal1, B Straume, R Lysaa, T Giverhaug, J Aarbakke.   

Abstract

Red blood cell (RBC) thiopurine methyltransferase (TPMT) metabolizes the cytotoxic drugs 6-mercaptopurine and azathioprine. RBC TPMT activity has been reported to predict clinical outcome in children with acute lymphoblastic leukaemia and in kidney transplant patients. We first suspected that the erythrocyte fraction affected the calculated TPMT activity when we examined intraindividual TPMT activities in kidney transplant recipients. We demonstrated that the erythrocyte fraction affected the calculated TPMT activity, thus causing a methodological inaccuracy. A low erythrocyte fraction gave an erroneously low TPMT activity. Mean variation of 7.0% was observed within the normal limits of the haematocrit level in healthy subjects. The slopes of the TPMT activity between erythrocyte fraction 0.1 and 0.5 were all significantly different from zero, and the activity displayed good linearity from erythrocyte fraction 0.2. There was a strong association between TPMT activity and erythrocyte fraction in a population sample of children, but not in two other population samples. We propose that the TPMT assay should be performed in lysates at a standardized erythrocyte fraction to avoid variation in activity due to the range of the haematocrit in a population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582469     DOI: 10.1007/bf00194340

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.

Authors:  P R Chocair; J A Duley; H A Simmonds; J S Cameron
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

2.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.

Authors:  R M Weinshilboum; F A Raymond; P A Pazmiño
Journal:  Clin Chim Acta       Date:  1978-05-02       Impact factor: 3.786

3.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

4.  Gender difference in red blood cell thiopurine methyltransferase activity.

Authors:  B Klemetsdal; E Wist; J Aarbakke
Journal:  Scand J Clin Lab Invest       Date:  1993-11       Impact factor: 1.713

5.  Thiopurine methyltransferase activity in a sample population of black subjects in Florida.

Authors:  C D Jones; C Smart; A Titus; G Blyden; M Dorvil; N Nwadike
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

6.  Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.

Authors:  C L Szumlanski; R Honchel; M C Scott; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1992-08

7.  Interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity.

Authors:  R Capdeville; B Mousson; G Bax; Y Bertrand; N Philippe
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Methylation pharmacogenetics: thiopurine methyltransferase as a model system.

Authors:  R M Weinshilboum
Journal:  Xenobiotica       Date:  1992 Sep-Oct       Impact factor: 1.908

9.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.

Authors:  W E Evans; M Horner; Y Q Chu; D Kalwinsky; W M Roberts
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

Review 10.  Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review.

Authors:  A Anstey; L Lennard; S C Mayou; J D Kirby
Journal:  J R Soc Med       Date:  1992-12       Impact factor: 18.000

View more
  1 in total

1.  Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.

Authors:  R A Lysaa; T Giverhaug; H L Wold; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.